Trial · NCT06993740
Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient
NCT06993740, Not applicable, Completed, Dharmais National Cancer Center Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient. Trials, record NCT06993740. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06993740
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient
- NCT number
- NCT06993740
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 60 participants, actual
- Lead sponsor
- Dharmais National Cancer Center Hospital
- Conditions
- Flap Monitoring, Inflammation, Thrombosis, Oxidative Stress, Glycocalyx, Anesthesia, Surgery, Flap Ischemia, Flap Necrosis, Flap Failure Risk Factors, Microsurgery
- Interventions
- NaCl 0,9%, Dexmedetomidine
- First posted
- 2025-05-29
- Last updated
- 2026-07-31
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Flap Viability Score | 48 hours postoperatively | Clinical evaluation of flap viability using a standardized scoring system based on four parameters: flap color, surface temperature, capillary refill time, and tissue turgor. Each parameter is scored individually and combined into a composite viability score. The total score reflects the degree of perfusion and tissue viability at 48 hours after microsurgical reconstruction. |
| Secondary | Tissue Syndecan-1 Expression | Intraoperative tissue sampling | Quantitative evaluation of syndecan-1 expression in flap tissue using immunohistochemistry (IHC) to assess endothelial glycocalyx integrity. Image analysis software will be used for objective quantification. |
| Secondary | Tissue Superoxide Dismutase 1 (SOD1) Expression | Intraoperative tissue sampling | Quantitative analysis of SOD1 expression in flap tissue using IHC, serving as a marker of oxidative stress response. Expression will be measured using image-based digital quantification. |
| Secondary | Interleukin-6 (IL-6) Level | Baseline (preoperative) and 12 hours postoperatively | Measurement of systemic IL-6 concentrations using Electrochemiluminescence Immunoassay (ECLIA) as an indicator of systemic inflammatory response. |
| Secondary | Interleukin-10 (IL-10) Level | Baseline (preoperative) and 12 hours postoperatively | Quantification of serum IL-10 levels using Enzyme-Linked Immunosorbent Assay (ELISA), to evaluate anti-inflammatory cytokine response. |
| Secondary | Vascular Endothelial Growth Factor (VEGF) Level | Baseline (preoperative) and 12 hours postoperatively | Assessment of systemic angiogenic activity by measuring VEGF levels in serum using ELISA. |
| Secondary | Plasminogen Activator Inhibitor-1 (PAI-1) Level | Baseline (preoperative) and 12 hours postoperatively | Measurement of PAI-1 levels in serum using ELISA to evaluate the fibrinolytic balance and thrombotic tendency. |
| Secondary | Microcirculation Assessment Using Sidestream Dark Field (SDF) Imaging | Immediate postoperative (sublingual site), 12 hours postoperative (flap tissue), and 48 hours postoperative (flap tissue) | Evaluation of microcirculatory parameters using SDF imaging, including vessel density, perfused vessel density, and flow pattern. Measurements will be conducted at the sublingual site and in the flap tissue at specified time points to assess systemic and local microcirculatory dynamics. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06993740
GET https://conductscience.org/api/trials/v1/NCT06993740/registered